Xencor Appoints Bart Cornelissen as CFO

Xencor, Inc. (NASDAQ: XNCR) has appointed Bart Cornelissen as its new Senior Vice President and Chief Financial Officer. Cornelissen brings over 20 years of experience in corporate financial planning, analysis, and transaction support to the role.

Before joining Xencor, Cornelissen served as the Vice President of Corporate Finance at Seagen Inc., where he played a key role in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. During his tenure, he oversaw significant revenue growth and dealmaking activity, including multiple licensing transactions and the company's $43 billion acquisition by Pfizer in 2023.

Prior to his role at Seagen, Cornelissen held positions at the Bill & Melinda Gates Foundation, where he enhanced financial analysis and strategic decision-making capabilities for the End Fund and served as the finance lead for malaria and neglected tropical disease initiatives. He also provided leadership to multiple finance teams in Austria, Germany, and Switzerland at DSM Nutritional Products and started his career at Novartis in roles within global financial planning and analysis.

Cornelissen holds an M.Sc. in Business Administration from the Rotterdam School of Management at Erasmus University.

In his new role at Xencor, Cornelissen will support planning and capitalization for the company's growth as it advances its internal pipeline, particularly focusing on XMAB bispecific T cell engagers in oncology through clinical development.

Xencor is a clinical-stage biopharmaceutical company with more than 20 candidates engineered with its XMAB® technology in clinical development, and three XMAB medicines already marketed by partners. The company's XMAB engineering technology enables small changes to a protein's structure, resulting in new mechanisms of therapeutic action. The market has reacted to these announcements by moving the company's shares -0.6% to a price of $21.38. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.